Download PDF
Semin Thromb Hemost 2007; 33(7): 621-642
DOI: 10.1055/s-2007-991530
© Thieme Medical Publishers

The Role of Hemostatic System Inhibitors in Malignancy

Marek Z. Wojtukiewicz1 , 2 , Ewa Sierko1 , 2 , Walter Kisiel3
  • 1Department of Oncology, Medical University, Bialystok, Poland
  • 2Comprehensive Cancer Center, Bialystok, Poland
  • 3Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico
Further Information

Publication History

Publication Date:
14 November 2007 (online)

    Permissions and Reprints

ABSTRACT

Malignancy is associated with alterations in the hemostatic system that present as thromboembolic or bleeding complications. Antineoplastic treatment further escalates blood coagulation and fibrinolytic abnormalities. Moreover, hemostatic system inhibitors play a role in tissue maintenance or, contrarily, contribute to cancer progression. The inhibitors regulate migration, proliferation, apoptosis, angiogenesis, and distant metastases formation, as well as interfere with host defense system mechanisms. They exhibit different functions depending on tumor type, histologic grade, and clinical stage of the disease. The activity of coagulation inhibitors underlies the pathomechanisms of some complications resulting from therapeutic procedures, such as radiation injury to normal tissues. Because coagulation activation is widely recognized to influence cancer growth and distant dissemination, numerous attempts were made to introduce various forms of coagulation inhibitors to antineoplastic treatment. This review summarizes up-to-date information on preclinical and clinical benefits and pitfalls of hemostatic system inhibitors administration in cancer, with special emphasis on tumor biology and prophylaxis and treatment of various complications observed in the course of malignant disease.

KEYWORDS

Hemostatic system inhibitors - cancer - TFPI - TFPI-2 - AT III - protein C system - protein Z - ZPI - fibrinolysis inhibitors - heparin

REFERENCES

  • 1 Callander N, Rapaport S I. Trousseau's syndrome.  West J Med. 1993;  158 364-371
    PubMedGoogle Scholar
  • 2 Naschitz J E, Yeshurun D, Lev L M. Thromboembolism in cancer.  Cancer. 1993;  71 1384-1390
    CrossrefPubMedGoogle Scholar
  • 3 Hillen H FP. Thrombosis in cancer patients.  Ann Oncol. 2000;  11(Suppl 3) 273-276
    Google Scholar
  • 4 Bick R L. Coagulation abnormalities in malignancy: a review.  Semin Thromb Hemost. 1992;  18 353-372
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Barnes J, Patel V, Lee M. Adenocarcinoma of the colon presenting with a Sister Mary Joseph's nodule and Trousseau's syndrome.  Cutis. 1995;  56 270-272
    PubMedGoogle Scholar
  • 6 Zacharski L R, Wojtukiewicz M Z, Costantini V, Ornstein D L, Memoli V A. Pathways of coagulation/fibrinolysis activation in malignancy.  Semin Thromb Hemost. 1992;  18 104-116
    PubMedGoogle Scholar
  • 7 Zacharski L R, Costantini V, Wojtukiewicz M Z, Memoli V A, Kudryk B J. Anticoagulants as cancer therapy.  Semin Oncol. 1990;  17 217-227
    PubMedGoogle Scholar
  • 8 Lindahl A K, Sandset P M, Abildgaard U, Adersson T R, Harbitz T B. High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer.  Acta Chir Scand. 1989;  155 389-393
    Google Scholar
  • 9 Lindahl A K, Odegaard O R, Sandset P M, Harbitz T B. Coagulation inhibition and activation in pancreatic cancer. Changes during progress of disease.  Cancer. 1992;  70 2067-2072
    PubMedGoogle Scholar
  • 10 Falanga A, Ofosu F A, Dalaini F et al.. The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions.  Blood Coagul Fibrinolysis. 1994;  5(Suppl 1) S19-S23
    PubMedGoogle Scholar
  • 11 Gerlach R, Scheuer T, Bohm M et al.. Increased levels of plasma tissue factor pathway inhibitor in patients with glioblastoma and intracerebral metastases.  Neurol Res. 2003;  25 335-338
    CrossrefPubMedGoogle Scholar
  • 12 Radziwon P, Schenk J F, Mazgajska K et al.. Tissue factor (TF) and inhibitor (TFPI) concentrations in patients with urinary tract tumors and haematological malignancies. [in Polish].  Pol Merkur Lekarski.. 2002;  13 308-311
    PubMedGoogle Scholar
  • 13 Beecken W D, Bentas W, Engels K et al.. Reduced plasma levels of coagulation factors in relation to prostate cancer.  Prostate. 2002;  53 160-167
    CrossrefPubMedGoogle Scholar
  • 14 Iversen L H, Okholm M, Thorlacius-Ussing O O. Pre- and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease - a preliminary study.  Thromb Haemost. 1996;  76 523-528
    PubMedGoogle Scholar
  • 15 Erman M, Abali H, Oran B et al.. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?.  Ann Oncol. 2004;  15 1622-1626
    CrossrefPubMedGoogle Scholar
  • 16 Bushman J E, Palmeri D, Whinna H C, Church F C. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia.  Leuk Res. 2000;  24 559-565
    CrossrefPubMedGoogle Scholar
  • 17 Noda K, Wada H, Yamada N et al.. Changes of hemostatic molecular markers after gynecological surgery.  Clin Appl Thromb Hemost. 2000;  6 197-201
    PubMedGoogle Scholar
  • 18 Lee J H, Lee K H, Kim S et al.. Relevance of protein C and S, antithrombin III, von Willebrand factor, and factor VII for the development of hepatic veno-occlusive disease in patients undergoing allogenic bone marrow transplantation: a prospective study.  Bone Marrow Transplant. 1998;  22 883-888
    CrossrefPubMedGoogle Scholar
  • 19 Park Y D, Yasui M, Yoshimoto T et al.. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation.  Bone Marrow Transplant. 1997;  19 915-920
    CrossrefPubMedGoogle Scholar
  • 20 Nürnberger W, Michelmann I, Burdach S, Göbel U. Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications.  Ann Hematol. 1998;  76 61-65
    CrossrefPubMedGoogle Scholar
  • 21 Matsumoto T, Wada H, Nishiyama H et al.. Hemostatic abnormalities and changes following bone marrow transplantation.  Clin Appl Thromb Hemost. 2004;  10 341-350
    CrossrefPubMedGoogle Scholar
  • 22 Broze Jr G J. Tissue factor pathway inhibitor.  Thromb Haemost. 1995;  74 90-93
    PubMedGoogle Scholar
  • 23 Lindahl A K, Abildgaard U, Stokke G. Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients.  Thromb Res. 1990;  59 651-656
    Google Scholar
  • 24 Iversen N, Lindahl A K, Abildgaard U. Elevated plasma levels of the factor Xa-TFPI complex in cancer patients.  Thromb Res. 2002;  105 33-36
    CrossrefPubMedGoogle Scholar
  • 25 Amirkhoshravi A, Meyer T, Chang J-Y, Amaya M, Siddiqui H, Francis J L. Tissue factor pathway inhibitor reduces experimental lung metastases of B16 melanoma.  Thromb Haemost. 2002;  87 930-936
    Google Scholar
  • 26 Hembrough T A, Swartz G M, Papathanassiu A et al.. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.  Cancer Res. 2003;  63 2997-3000
    Google Scholar
  • 27 Bromberg M E, Konigsberg W H, Madison J F, Pawashe A, Garen A. Tissue factor promotes metastasis by a pathway independent of blood coagulation.  Proc Natl Acad Sci USA. 1995;  92 8205-8209
    Google Scholar
  • 28 Müller B M, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor dependent experimental metastasis.  J Clin Invest. 1998;  101 1372-1378
    Google Scholar
  • 29 Tang D G, Honn K V. Adhesion molecules and tumor metastasis: an update.  Invasion Metastasis. 1994-95;  14 109-122
    PubMedGoogle Scholar
  • 30 Honn K V, Tang G T, Chen Y Q. Platelets and cancer metastasis: more than an epiphenomenon.  Semin Thromb Hemost. 1992;  18 392-415
    PubMedGoogle Scholar
  • 31 Donnelly K M, Bromberg M E, Milstone A et al.. Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro.  Thromb Haemost. 1998;  79 1041-1047
    Google Scholar
  • 32 Chachinian A P, Propert K J, Ware J H et al.. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B.  J Clin Oncol. 1989;  7 993-1002
    PubMedGoogle Scholar
  • 33 Hejna M, Raderer M, Zielinsky C C. Inhibition of metastasis by anticoagulants.  J Natl Cancer Inst. 1999;  91 22-36
    CrossrefPubMedGoogle Scholar
  • 34 Lebeau B, Chastang C, Brechot J M et al.. Subcutaneous heparin treatment increases survival in small-cell lung cancer.  Cancer. 1994;  74 38-45
    CrossrefPubMedGoogle Scholar
  • 35 Wojtukiewicz M Z, Kozłowski L, Ostrowska K, Dmitruk A, Zacharski L R. Low molecular heparin treatment for malignant melanoma: a pilot clinical trial.  Thromb Haemost. 2003;  89 405-407
    PubMedGoogle Scholar
  • 36 Zacharski L R, Henderson W G, Rickles F R et al.. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate.  Cancer. 1984;  53 2046-2052
    CrossrefPubMedGoogle Scholar
  • 37 Kakkar A K, Levine M N, Kadziola Z et al.. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).  J Clin Oncol. 2004;  22 1944-1948
    CrossrefPubMedGoogle Scholar
  • 38 Mousa S A, Linhardt R, Francis J, Amirkhosravi A. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.  Thromb Haemost. 2006;  96 816-821
    Google Scholar
  • 39 Wojtukiewicz M Z, Sierko E, Rak J. Contribution of the hemostatic system to angiogenesis in cancer.  Semin Thromb Hemost. 2004;  30 5-20
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Wojtukiewicz M Z, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy.  Neoplasia. 2001;  3 371-384
    Google Scholar
  • 41 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases.  Nat Med. 1995;  1 27-31
    CrossrefPubMedGoogle Scholar
  • 42 Shoji M, Abe K, Nawroth P P et al.. Molecular mechanisms linking thrombosis and angiogenesis in cancer.  Trends Cardiovasc Med. 1997;  7 52-59
    Google Scholar
  • 43 Ott I, Fischer E G, Miyagi Y et al.. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280.  J Cell Biol. 1998;  140 1241-1253
    Google Scholar
  • 44 Belting M, Dorrell M I, Sandgren S et al.. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling.  Nat Med. 2004;  10 502-509
    Google Scholar
  • 45 Ahamed J, Belting M, Ruf W. Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1.  Blood. 2005;  105 2384-2391
    Google Scholar
  • 46 Amirkhosravi A, Meyer T, Desai H et al.. TFPI carboxy-terminal peptide exhibits anticoagulant activity and suppresses proliferation of melanoma and endothelial cells.  Blood. 2001;  98 66b
    Google Scholar
  • 47 Werling R W, Zacharski L R, Kisiel W, Bajaj S P, Memoli V A, Rousseau S A. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues.  Thromb Haemost. 1993;  69 366-369
    Google Scholar
  • 48 Sierko E, Zawadzki R J, Zimnoch L, Sulkowski S, Wojtukiewicz M Z. Expression of blood coagulation inhibitors in colon cancer.  , [in Polish] Pol Merkur Lekarski. 2006;  20 462-467
    PubMedGoogle Scholar
  • 49 Wojtukiewicz M Z, Rucińska M, Zacharski L R et al.. Localization of blood coagulation factors in situ in pancreatic carcinoma.  Thromb Haemost. 2001;  86 1416-1420
    PubMedGoogle Scholar
  • 50 Wojtukiewicz M Z, Sierko E, Zacharski L R, Zimnoch L, Kudryk B, Kisiel B. Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer.  Semin Thromb Hemost. 2003;  29 291-299
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Wojtukiewicz M Z, Zacharski L R, Rucińska M et al.. Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma.  Thromb Haemost. 1999;  82 1659-1662
    PubMedGoogle Scholar
  • 52 Sierko E, Sawicki Z, Butkiewicz A, Zimnoch L, Kisiel W, Wojtukiewicz M. TFPI (tissue factor pathway inhibitor) is present in breast cancer tumor.  , [abstract] Blood. 2006;  108 4035
    CrossrefPubMedGoogle Scholar
  • 53 Kurer M A. Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells.  Mol Biol Rep. 2006; (abst); 
    PubMedGoogle Scholar
  • 54 Sevinsky J R, Rao L VM, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway.  J Cell Biol. 1996;  133 293-304
    Google Scholar
  • 55 Ruf W, Müller B M. Tissue factor in cancer angiogenesis and metastasis.  Curr Opin Hematol. 1996;  3 379-384
    CrossrefPubMedGoogle Scholar
  • 56 Ruf W, Müller B M. Tissue factor signaling.  Thromb Haemost. 1999;  82 175-182
    PubMedGoogle Scholar
  • 57 Wojtukiewicz M Z, Zacharski L R, Memoli V A et al.. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung.  Cancer. 1990;  65 481-485
    PubMedGoogle Scholar
  • 58 Wojtukiewicz M Z, Zacharski L R, Memoli V A et al.. Indirect activation of blood coagulation in colon cancer.  Thromb Haemost. 1989;  62 1062-1066
    PubMedGoogle Scholar
  • 59 Fischer E G, Riewald M, Huang H Y et al.. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor.  J Clin Invest. 1999;  104 1213-1221
    Google Scholar
  • 60 Ruf W, Seftor E A, Petrovan R J et al.. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry.  Cancer Res. 2003;  63 5381-5389
    PubMedGoogle Scholar
  • 61 Sprecher C A, Kisiel W, Mathews S, Foster D C. Molecular cloning, expression, and partial characterization of a second tissue-factor-pathway-inhibitor.  Proc Natl Acad Sci USA. 1994;  91 3353-3357
    Google Scholar
  • 62 Peterson L C, Sprecher C A, Foster D C, Blumberg H, Hamamoto T, Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.  Biochemistry. 1996;  35 266-272
    Google Scholar
  • 63 Kisiel W, Sprecher C A, Foster D C. Evidence that a second tissue factor pathway inhibitor (TFPI-2) and placental protein 5 are equivalent.  Blood. 1994;  84 4384-4385
    PubMedGoogle Scholar
  • 64 Chand H S, Schmidt A E, Bajaj S P, Kisiel W. Structure-function analysis of the reactive site in the first Kunitz-type domain of human factor pathway inhibitor-2.  J Biol Chem. 2004;  279 17500-17507
    CrossrefPubMedGoogle Scholar
  • 65 Bohn H, Winckler W. Isolierung und Charakterisierung des Plazenta-Proteins PP5.  Arch Gynaek. 1977;  223 179-186
    PubMedGoogle Scholar
  • 66 Siiteri J E, Koistinen H AT, Salem H AT, Bohn H, Seppaelae M. Placental protein 5 is related to blood coagulation and fibrinolytic systems.  Life Sci. 1982;  30 1885-1891
    CrossrefPubMedGoogle Scholar
  • 67 Meisser A, Bischof P, Bohn H. Placental protein 5 (PP5) inhibits thrombin-induced coagulation of fibrinogen.  Arch Gynecol. 1985;  236 197-201
    CrossrefPubMedGoogle Scholar
  • 68 Miyagi Y, Koshikawa N, Yasumitsu H et al.. cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: identification as placental protein 5 and tissue factor pathway inhibitor-2.  J Biochem (Tokyo). 1994;  116 939-942
    Google Scholar
  • 69 Iino M, Foster D C, Kisiel W. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2.  Arterioscler Thromb Vasc Biol. 1998;  18 40-46
    PubMedGoogle Scholar
  • 70 Wahlstroem T, Bohn H, Seppaelae M. Immunohistochemical demonstration of placental protein 5 (PP5) - like material in the seminal vesicles and the ampullar part of vas deferens.  Life Sci. 1982;  31 2723-2725
    CrossrefPubMedGoogle Scholar
  • 71 Wojtukiewicz M Z, Sierko E, Zimnoch L, Kozłowski L, Sulkowski S, Kisiel W. Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue.  Thromb Haemost. 2003;  90 140-146
    PubMedGoogle Scholar
  • 72 Rollin J, Régina S, Vourc'h P et al.. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer.  Lung Cancer. 2007;  56 273-280
    CrossrefPubMedGoogle Scholar
  • 73 Rollin J, Iochmann S, Bléchet C et al.. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer.  Br J Cancer. 2005;  92 775-783
    CrossrefPubMedGoogle Scholar
  • 74 Wong C M, Ng Y L, Lee J M et al.. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma.  Hepatology. 2007;  45 1129-1138
    CrossrefPubMedGoogle Scholar
  • 75 Rao C N, Lakka S S, Kin Y et al.. Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas.  Clin Cancer Res. 2001;  7 570-576
    Google Scholar
  • 76 Sato N, Parker A R, Fukushima N et al.. Epigenetic inactivation of TFPI-2 as a mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma.  Oncogene. 2005;  24 850-858
    CrossrefPubMedGoogle Scholar
  • 77 Udagawa K, Miyagi Y, Hirahara F et al.. Specific expression of PP5/TFPI-2 mRNA by syncytiotrophoblasts in human placenta as revealed by in situ hybridization.  Placenta. 1998;  19 217-223
    CrossrefPubMedGoogle Scholar
  • 78 Izumi H, Takahashi C, Oh J, Noda M. Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogene.  FEBS Lett. 2000;  481 3136
    PubMedGoogle Scholar
  • 79 Saito E, Okamoto A, Saito M et al.. Genes associated with the genesis of leiomyoma of the uterus in a commonly deleted chromosomal region at 7q22.  Oncol Rep. 2005;  13 469-472
    PubMedGoogle Scholar
  • 80 Dong J T. Chromosomal deletions and tumor suppressor genes in prostate cancer.  Cancer Metastasis Rev. 2001;  20 173-193
    CrossrefPubMedGoogle Scholar
  • 81 Sell S M, Tullis C, Stracner D, Song C Y, Gewin J. Minimal interval defined on 7q in uterine leiomyoma.  Cancer Genet Cytogenet. 2005;  157 67-69
    CrossrefPubMedGoogle Scholar
  • 82 Nobeyama Y, Okochi-Takada E, Furuta J et al.. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas.  Int J Cancer. 2007;  121 301-307
    CrossrefPubMedGoogle Scholar
  • 83 Steiner F A, Hong J A, Fischette M R et al.. Sequential 5-aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells.  Oncogene. 2005;  24 2386-2397
    CrossrefPubMedGoogle Scholar
  • 84 Konduri S D, Srivenugopal K S, Yanamandra N et al.. Promoter methylation and silencind of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human gliomas cells.  Oncogene. 2003;  22 4509-4516
    CrossrefPubMedGoogle Scholar
  • 85 Jiang P, Watanabe H, Okada G et al.. Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic carcinoma.  Cancer Sci. 2006;  97 1267-1272
    CrossrefPubMedGoogle Scholar
  • 86 Rao C N, Segawa T, Navari J R et al.. Methylation of TFPI-2 gene is not the sole cause of its silencing.  Int J Oncol. 2003;  22 843-848
    PubMedGoogle Scholar
  • 87 Kempaiah P, Chand H S, Kisiel W. Identification of a human TFPI-2 slice variant that is upregulated in human tumor tissue.  Mol Cancer. 2007;  6 20-31
    CrossrefPubMedGoogle Scholar
  • 88 Torres-Collado A X, Kisiel W, Iruela-Arispe M L, Rodriguez-Manzaneque J C. ADAMTS1 interacts with, cleaves, and modifies the extracellular location of the matrix inhibitor tissue factor pathway inhibitor-2.  J Biol Chem. 2006;  281 17827-17837
    CrossrefPubMedGoogle Scholar
  • 89 Jin M, Udagawa K, Miyagi E et al.. Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells in vitro and in vivo.  Gynecol Oncol. 2001;  83 325-333
    CrossrefPubMedGoogle Scholar
  • 90 Lakka S S, Konduri S D, Mohanam S, Nicolson G L, Rao J S. In vitro modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2.  Clin Exp Metastasis. 2000;  18 239-244
    Google Scholar
  • 91 Konduri S D, Rao C N, Chandrasekar N et al.. A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion.  Oncogene. 2001;  20 6938-6945
    Google Scholar
  • 92 Rao C N, Cook B, Liu Y et al.. HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI.  Int J Cancer. 1998;  76 749-756
    Google Scholar
  • 93 Konduri S D, Tasiou A, Chandrasekar N, Rao J S. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2) decreases the invasiveness of prostate cancer cells in vitro.  Int J Oncol. 2001;  18 127-131
    Google Scholar
  • 94 Konduri S D, Tasiou A, Chandrasekar N, Nicolson G L, Rao J S. Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion.  Clin Exp Metastasis. 2000;  18 303-308
    CrossrefPubMedGoogle Scholar
  • 95 Carroll V, Binder B. The role of the plasminogen activation system in cancer.  Semin Thromb Hemost. 1999;  25 183-197
    Article in Thieme ConnectPubMedGoogle Scholar
  • 96 Siiteri J E, Koistinen H AT, Salem H AT, Bohn H, Seppaelae M. Placental protein 5 is related to blood coagulation and fibrinolytic systems.  Life Sci. 1982;  30 1885-1891
    CrossrefPubMedGoogle Scholar
  • 97 Rao C N, Mohanam S, Puppala A, Rao J S. Regulation of pro-MMP-1 and pro-MMP-3 activation by tissue factor pathway inhibitor-2/matrix associated serine protease inhibitor.  Biochem Biophys Res Commun. 1999;  255 94-98
    CrossrefPubMedGoogle Scholar
  • 98 Herman M P, Sukhova G K, Kisiel W et al.. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis.  J Clin Invest. 2001;  107 1117-1126
    PubMedGoogle Scholar
  • 99 Du X, Chand H S, Kisiel W. Human tissue factor pathway inhibitor-2 does not bind or inhibit activated matrix metalloproteinase-1.  Biochim Biophys Acta. 2003;  1621 242-245
    PubMedGoogle Scholar
  • 100 Kondraganti S, Gondi C S, Gujrati M et al.. Restoration of tissue factor patway inhibitor inhibits invasion and trumor growth in vitro and in vivo a malignant meningioma cell line.  Int J Oncol. 2006;  29 25-32
    Google Scholar
  • 101 Sun Y, Xie M, Liu M, Jin D, Li P. Growth suppression of human laryngeal squamous cell carcinoma by adenovirus-mediated tissue factor pathway inhibitor gene 2.  Laryngoscope. 2006;  116 596-601
    CrossrefPubMedGoogle Scholar
  • 102 Tasiou A, Konduri S D, Yanamandra N et al.. A novel role of tissue factor pathway inhibitor-2 in apoptosis of malignant human gliomas.  Int J Oncol. 2001;  19 591-597
    Google Scholar
  • 103 George J, Gondi C S, Dinh D H, Gujrati M, Rao J S. Restoration of tissue factor patway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis.  Clin Cancer Res. 2007;  13 3507-3517
    CrossrefPubMedGoogle Scholar
  • 104 Shoji M, Hancock W W, Abe K et al.. Activation of blood coagulation and angiogenesis in cancer.  Am J Pathol. 1998;  152 399-411
    PubMedGoogle Scholar
  • 105 Rao L VM. Tissue factor as a tumor procoagulant.  Cancer Metastasis Rev. 1992;  11 249-266
    CrossrefPubMedGoogle Scholar
  • 106 Neaud V, Hisaka T, Monvoisin A et al.. Paradoxical pro-invasive effect of the serine proteinase inhibitor tissue factor pathway inhibitor-2 on human hepatocellular carcinoma cells.  J Biol Chem. 2000;  275 35565-35569
    CrossrefPubMedGoogle Scholar
  • 107 Yanamandra N, Kondraganti S, Gondi C S et al.. Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line.  Int J Cancer. 2005;  115 998-1005
    CrossrefPubMedGoogle Scholar
  • 108 Ivanciu L, Gerard R D, Tang H, Lupu F, Lupu C. Adenovirus-mediated expression of tissue factor pathway inhibitor-2 inhibits endothelial cell migration and angiogenesis.  Arterioscler Thromb Vasc Biol. 2007;  27 310-316
    Google Scholar
  • 109 Xu Z, Maiti D, Kisiel W, Duh E L. Tissue factor pathway inhibitor-2 is up-regulated by vascular endothelial growth factor and suppresses growth factor-induced proliferation of endothelial cells.  Arterioscler Thromb Vasc Biol. 2006;  26 2819-2825
    CrossrefPubMedGoogle Scholar
  • 110 Ruf W, Seftor E A, Petrovan R J et al.. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry.  Cancer Res. 2003;  63 5381-5389
    PubMedGoogle Scholar
  • 111 Han X, Fiehler R, Broze Jr G J. Characterization of the protein Z-dependent protease inhibitor.  Blood. 2000;  96 3049-3055
    PubMedGoogle Scholar
  • 112 Ichinose A, Takeya H, Espling E, Iwanaga S, Kisiel W, Davie E W. Amino acid sequence of human protein Z, a vitamin K-dependent plasma glycoprotein.  Biochem Biophys Res Commun. 1990;  172 1139-1144
    CrossrefPubMedGoogle Scholar
  • 113 Sierko E, Tokajuk P, Ramlau R et al.. Immunohistochemical localization of protein Z (ZP) and protein Z-dependent protease inhibitor (ZPI) in situ in human malignant tumors.  [abstract] J Thromb Haemost. 2005;  3(Suppl 1) P0718
    CrossrefPubMedGoogle Scholar
  • 114 Sierko E, Wojtukiewicz M Z, Tokajuk P et al.. Expression of protein Z (PZ) and protein Z-dependent protease inhibitor (ZPI) in situ in human malignant tissues [abstract].  Blood. 2005;  106 1028
    PubMedGoogle Scholar
  • 115 Sierko E, Ramlau R, Zimnoch L, Broze G J, Wojtukiewicz M. Expression of protein Z-dependent protease inhibitor (ZPI) in situ in different malignant tumors [abstract].  Blood. 2004;  104 3959
    PubMedGoogle Scholar
  • 116 Sierko E, Tokajuk P, Ramlau R, Zimnoch L, Kisiel W, Wojtukiewicz M. Localization of protein Z (PZ) in situ in human neoplastic tissues.  , [abstract] Blood. 2004;  104 3958
    CrossrefPubMedGoogle Scholar
  • 117 Roemisch J, Gray E, Hoffmann J N, Wiedermann C J. Antithrombin: a new look at the actions of a serine protease inhibitor.  Blood Coagul Fibrinolysis. 2002;  13 657-670
    CrossrefPubMedGoogle Scholar
  • 118 Wojtukiewicz M Z, Rucińska M, Kloczko J, Dib A, Galar M. Profiles of plasma serpins in patients with advanced malignant melanoma, gastric cancer and breast cancer.  Haemostasis. 1998;  28 7-13
    CrossrefPubMedGoogle Scholar
  • 119 Andersen B S, Rahr H B, Sørensen J V. Determination of coagulation inhibitor levels and resistance to activated protein C in patients undergoing gastric surgery for benign and malignant disorders.  Haemostasis. 1997;  27 157-162
    PubMedGoogle Scholar
  • 120 Honegger H, Anderson N, Hewitt L A, Tullis J L. Antithrombin III profiles in malignancy, relationship between primary tumors and metastatic sites.  Thromb Haemost. 1981;  46 500-503
    PubMedGoogle Scholar
  • 121 Onizuka K, Migita S, Yamada H, Matsumoto I. Serum protein fractions in patients with laryngeal cancer undergoing radiation therapy. Possibility as a prognostic factor.  , [in Japanese] [abstract] Fukuoka Igaku Zasshi. 1999;  90 46-58
    PubMedGoogle Scholar
  • 122 Unsal E, Atalay F, Atikcan S, Yilmaz A. Prognostic significance of hemostatic parameters in patients with lung cancer.  Respir Med. 2004;  98 93-98
    CrossrefPubMedGoogle Scholar
  • 123 Bartoloni C, Guidi L, Tricerri A et al.. Latent coagulation disorders evaluated by the assay of plasma thrombin-antithrombin III complex in a large series of ‘solid tumors’.  Oncology. 1992;  49 426-430
    PubMedGoogle Scholar
  • 124 Ozyilkan O, Baltali E, Ozdemir O, Tekuzman G, Kirazli S, Firat D. Haemostatic changes; plasma levels of alpha2-antiplasmin-plasmin complex and thrombin-antithrombin III complex in female breast cancer.  Tumori. 1998;  84 364-367
    PubMedGoogle Scholar
  • 125 Wojtukiewicz M Z, Tang T G, Ciarelli J J et al.. Thrombin increases the metastatic potential of tumor cell.  Int J Cancer. 1993;  54 793-806
    CrossrefPubMedGoogle Scholar
  • 126 Wojtukiewicz M Z, Tang T G, Nelson K K, Walz D A, Diglio C A, Honn K V. Thrombin enhances tumor cell adhesive and metastatic properties via increased αIIbß3 expression on the cell surface.  Thromb Res. 1992;  68 233-245
    CrossrefPubMedGoogle Scholar
  • 127 Sierko E, Wojtukiewicz M Z. Platelets and angiogenesis in malignancy.  Semin Thromb Hemost. 2004;  30 95-108
    Article in Thieme ConnectPubMedGoogle Scholar
  • 128 O'Reilly M S, Pirie-Shepherd S, Lane W S, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin.  Science. 1999;  285 1926-1928
    CrossrefPubMedGoogle Scholar
  • 129 Falanga A, Rickles F R. Patophysiology of the thrombophilic state in the cancer patient.  Semin Thromb Hemost. 1999;  25 173-182
    Article in Thieme ConnectPubMedGoogle Scholar
  • 130 Esmon C T. Inflammation and the activated protein C anticoagulant pathway.  Semin Thromb Hemost. 2006;  32(suppl 1) 49-60
    Article in Thieme ConnectPubMedGoogle Scholar
  • 131 Esmon C T. Role of coagulation inhibitors in inflammation.  Thromb Haemost. 2001;  86 51-56
    PubMedGoogle Scholar
  • 132 Esmon C T. The endothelial cell protein C receptor.  Thromb Haemost. 2000;  83 639-643
    PubMedGoogle Scholar
  • 133 Ellis C N, Boggs H W, Slagle G W, Cole P A, Coyle D J, Blakemore W S. Protein C activity, stage of disease, and vascular thrombosis in colon carcinoma.  Am J Surg. 1992;  163 78-81
    CrossrefPubMedGoogle Scholar
  • 134 Green D, Maliekel K, Sushko E, Akhtar R, Soff G A. Activated-protein-C resistance in cancer patients.  Haemostasis. 1997;  27 112-118
    PubMedGoogle Scholar
  • 135 De Lucia D, De Francesco F, Marotta R et al.. Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma.  Exp Oncol. 2005;  27 159-161
    PubMedGoogle Scholar
  • 136 De Lucia D, De Vita F, Orditura M et al.. Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C.  Tumori. 1997;  83 948-952
    PubMedGoogle Scholar
  • 137 Paspatis G A, Sfyridaki A, Papanikolaou N et al.. Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer.  Pathophysiol Haemost Thromb. 2002;  32 2-7
    CrossrefPubMedGoogle Scholar
  • 138 Nijziel M R, van Oerle R, Christella M et al.. Acquired resistance to activated protein C in breast cancer patients.  Br J Haematol. 2003;  120 117-122
    CrossrefPubMedGoogle Scholar
  • 139 Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (APCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.  Br J Haematol. 2006;  134 399-405
    CrossrefPubMedGoogle Scholar
  • 140 Wojtukiewicz M Z, Zacharski L R, Memoli V A et al.. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ.  Am J Clin Pathol. 1990;  93 516-521
    PubMedGoogle Scholar
  • 141 Wojtukiewicz M Z, Zacharski L R, Memoli V A et al.. Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue.  Cancer. 1991;  67 1377-1381
    PubMedGoogle Scholar
  • 142 Nijziel M R, van Oerle R, van Pampus E C, de Vet H C, Hillen H F, Hamulyák K. Increased D-dimer levels correlate with binding of activated protein C, but not tissue factor expression, on peripheral blood monocytes in cancer patients.  Am J Hematol. 2000;  64 282-286
    CrossrefPubMedGoogle Scholar
  • 143 Cheng T, Liu D, Griffin J H et al.. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective.  Nat Med. 2003;  9 338-342
    CrossrefPubMedGoogle Scholar
  • 144 Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR-1-dependent sphingosine1-phosphate receptor-1 crossactivation.  Blood. 2005;  105 3178-3184
    CrossrefPubMedGoogle Scholar
  • 145 Guo H, Liu D, Gelbard H et al.. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 2.  Neuron. 2004;  41 563-572
    CrossrefPubMedGoogle Scholar
  • 146 Wojtukiewicz M Z, Tang T G, Ben-Josef E, Renaud C, Walz D A, Honn K V. Solid tumor cells express functional “tethered ligand” thrombin receptor.  Cancer Res. 1995;  55 698-704
    PubMedGoogle Scholar
  • 147 Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 cell induces cell proliferation and motility in human colon cancer cells.  Am J Pathol. 2003;  162 1503-1513
    PubMedGoogle Scholar
  • 148 Black P C, Mize G J, Karlin P et al.. Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer.  Prostate. 2007;  67 743-756
    CrossrefPubMedGoogle Scholar
  • 149 Kaufmann R, Rahn S, Pollrich K et al.. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4.  J Cell Physiol. 2007;  211 699-707
    CrossrefPubMedGoogle Scholar
  • 150 Beaulieu L M, Church F C. Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1.  Exp Cell Res. 2007;  313 677-687
    CrossrefPubMedGoogle Scholar
  • 151 Granovsky-Grisaru S, Zaidoun S, Grisaru D et al.. The pattern of protease activated receptor 1 (PAR1) expression in endometrial carcinoma.  Gynecol Oncol. 2006;  103 802-806
    CrossrefPubMedGoogle Scholar
  • 152 Ghio P, Cappia S, Selvaggi G et al.. Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-small-cell lung cancer.  Clin Lung Cancer. 2006;  7 395-400
    PubMedGoogle Scholar
  • 153 Bergmann S, Junker K, Henklein P, Hollenberg M D, Settmacher U, Kaufmann R. PAR-type thrombin receptors in renal carcinoma cells: PAR1-mediated EGFR activation promotes cell migration.  Oncol Rep. 2006;  15 889-893
    PubMedGoogle Scholar
  • 154 Massi D, Naldini A, Ardinghi C et al.. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.  Hum Pathol. 2005;  36 676-685
    CrossrefPubMedGoogle Scholar
  • 155 Zhang X, Hunt J L, Landsittel D P et al.. Correlation of protease-activated receptor-1 with differentiation markers in squamous cell carcinoma of the head and neck and its implication in lymph node metastasis.  Clin Cancer Res. 2004;  10 8451-8459
    CrossrefPubMedGoogle Scholar
  • 156 Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit R. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.  Int J Cancer. 2005;  113 372-378
    CrossrefPubMedGoogle Scholar
  • 157 Rudroff C, Seibold S, Kaufmann R et al.. Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro.  Clin Exp Metastasis. 2002;  19 181-189
    CrossrefPubMedGoogle Scholar
  • 158 Okamoto T, Nishibori M, Sawada K et al.. The effects of stimulating protease-activated receptor-1 and -2 in A172 human glioblastoma.  J Neural Transm. 2001;  108 125-140
    CrossrefPubMedGoogle Scholar
  • 159 Even-Ram S, Uziely B, Cohen P et al.. Thrombin receptor overexpression in malignant and physiological invasion processes.  Nat Med. 1998;  4 909-914
    PubMedGoogle Scholar
  • 160 Pleyer L, Went P, Russ G et al.. Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C.  Wien Klin Wochenschr. 2007;  119 254-258
    CrossrefPubMedGoogle Scholar
  • 161 Nguyen M, Arkell J, Jackson C J. Activated protein C directly activates human endothelial gelatinase A.  J Biol Chem. 2000;  275 9095-9098
    CrossrefPubMedGoogle Scholar
  • 162 Papadopoulou S, Scorilas A, Arnogianaki N et al.. Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa.  Tumour Biol. 2001;  22 383-389
    PubMedGoogle Scholar
  • 163 Juuti A, Lundin I, Nordling S, Louhimo J, Haglud C. Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer.  Oncology. 2006;  71 61-68
    CrossrefPubMedGoogle Scholar
  • 164 Patel B P, Shah S V, Shukla S N, Shah P M, Patel P S. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer.  Head Neck. 2007;  29 564-572
    CrossrefPubMedGoogle Scholar
  • 165 Wu C Y, Wu M S, Chen Y J et al.. Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer.  Eur J Cancer. 2007;  43 799-808
    CrossrefPubMedGoogle Scholar
  • 166 Uchiba M, Okajima K, Oike Y et al.. Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo.  Circ Res. 2004;  95 34-41
    CrossrefPubMedGoogle Scholar
  • 167 Tsuneyoshi N, Fukudome K, Horiguchi S et al.. Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines.  Thromb Haemost. 2001;  85 356-361
    PubMedGoogle Scholar
  • 168 Scheffer G L, Flens M J, Hageman S, Izquierdo M A, Shoemaker R H, Scheper R J. Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells.  Eur J Cancer. 2002;  38 1535-1542
    CrossrefPubMedGoogle Scholar
  • 169 Wang X, Wang E, Kavanagh J J, Freedman S S. Ovarian cancer, the coagulation pathway, and inflammation.  J Transl Med. 2005;  3 25
    CrossrefPubMedGoogle Scholar
  • 170 Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization.  J Biol Chem. 1983;  258 163-168
    PubMedGoogle Scholar
  • 171 Sierko E, Tokajuk P, Zimnoch L, Wojtukiewicz M Z. The location of components of fibrinolytic system in laryngeal cancer.  , [in Polish] Pol Merkur Lekarski. 2003;  15 81-85
    PubMedGoogle Scholar
  • 172 Wakita T, Hayashi T, Nishioka J et al.. Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreases in renal cell carcinoma.  Int J Cancer. 2004;  108 516-523
    CrossrefPubMedGoogle Scholar
  • 173 Castello R, Landete J M, Espana F et al.. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.  Thromb Res. 2007;  120 753-762
    CrossrefPubMedGoogle Scholar
  • 174 Ordonez N-G. Transitional cell carcinomas of the ovary and bladder are immunophenotypically different.  Histopathology. 2000;  36 433-438
    CrossrefPubMedGoogle Scholar
  • 175 Ogawa H, Yonezawa S, Maruyama I et al.. Expression of thrombomodulin in squamous cell carcinoma of the lung: its relationship to lymph node metastasis and prognosis of the patients.  Cancer Lett. 2000;  149 95-103
    CrossrefPubMedGoogle Scholar
  • 176 Hamatake M, Ishida T, Mitsudomi T, Akazawa K, Sugimachi K. Prognostic value and pathological correlation of thrombomodulin in squamous cell carcinoma of the human lung.  Clin Cancer Res. 1996;  2 763-766
    PubMedGoogle Scholar
  • 177 Tezuka Y, Yonezawa S, Maruyama I et al.. Expression of thrombomodulin in esophageal squamous cell carcinoma and its relationship to lymph node metastasis.  Cancer Res. 1995;  55 4196-4200
    PubMedGoogle Scholar
  • 178 Tamura A, Hebisawa A, Hayashi K et al.. Prognostic significance of thrombomodulin expression and vascular invasion in stage I squamous cell carcinoma of the lung.  Lung Cancer. 2001;  34 375-382
    CrossrefPubMedGoogle Scholar
  • 179 Tabata M, Sugihara K, Yonezawa S, Yamashita S, Maruyma I. An immunihistochemical study of thrombomodulin in oral squamous cell carcinoma and its association with invasive and metastatic potential.  J Oral Pathol Med. 1997;  26 258-264
    CrossrefPubMedGoogle Scholar
  • 180 Hernández Gaspar R, de los Toyos J R, Alvarez Marcos C, Riera J R, Sampedro A. Quatitative immunohistochemical analyses of the expression of the E-cadherin, thrombomodulin, CD44H and CD44v6 in primary tumours of the pharynx, larynx squamous cell carcinoma and their lymph node metastases.  Anal Cell Pathol. 1999;  18 183-190
    PubMedGoogle Scholar
  • 181 Kim S J, Shiba E, Ischi H et al.. Thrombomodulin is a new biological and prognostic marker for breast cancer: an Immunohistochemical study.  Anticancer Res. 1997;  17 2319-2323
    PubMedGoogle Scholar
  • 182 Hanly A M, Redmond M, Winter D C et al.. Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival.  Br J Cancer. 2006;  94 1320-1325
    CrossrefPubMedGoogle Scholar
  • 183 Wilhelm S, Schmitt M, Parkinson J, Kuhn W, Graeff H, Wilhelm O G. Thrombomodulin, a receptor for serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc.  Int J Oncol. 1998;  13 645-651
    PubMedGoogle Scholar
  • 184 Oikawa T, Kushuhara M, Ischikawa S et al.. Production of endothelin-1 and thrombomodulin by human pancreatic canccer cells.  Br J Cancer. 1994;  69 1059-1064
    PubMedGoogle Scholar
  • 185 Wojtukiewicz M Z, Zimnoch L, Kloczko J et al.. Heterogeneous expression of endothelial cell-associated proteins in gliomas of different malignancy. In: Messmer K, Kübler WM 6th World Congress for Microcirculation. Bologna, Italy; Monduzzi Editore 1996: 1007-1010
    Google Scholar
  • 186 Maruno M, Yoshimine T, Isaka T, Kuroda R, Ischi H, Hayakawa T J. Expression of thrombolmodulin in astrocytomas of various malignancy and in gliotic and normal brains.  J Neurooncol. 1994;  19 155-160
    CrossrefPubMedGoogle Scholar
  • 187 Furuta J, Kaneda A, Umebayashi Y, Otsuka F, Sugimura T, Ushijama T. Silencing of the thrombomodulin gene in human malignant melanoma.  Melanoma Res. 2005;  15 15-20
    CrossrefPubMedGoogle Scholar
  • 188 Zhang Y, Weiler-Guettler H, Chen J et al.. Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity.  J Clin Invest. 1998;  101 1301-1309
    PubMedGoogle Scholar
  • 189 Huang H C, Shi G Y, Jiang S J et al.. Thrombomodulin-mediated cell adhesion: involvement of its lectin-like domain.  J Biol Chem. 2003;  278 46750-46759
    CrossrefPubMedGoogle Scholar
  • 190 Matsushita Y, Yoshiie K, Imamura Y et al.. A subcloned human esophageal squamous cell carcinoma cell line with low thrombomodulin expression showed increased invasiveness compared with a high thrombomodulin - expressing clone -thrombomodulin as a possible candidate for an adhesion molecule of squamous cell carcinoma.  Cancer Lett. 1998;  127 195-201
    CrossrefPubMedGoogle Scholar
  • 191 Suechiro T, Shimada M, Matsumata T, Taketomi A, Yamamoto K, Sugimachi K. Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma.  Hepatology. 1995;  21 1285-1290
    PubMedGoogle Scholar
  • 192 Iino S, Abeyama K, Kawahara K et al.. The antimetastatic role of thrombomodulin expression in islet cell-derived tumors and its diagnostic value.  Clin Cancer Res. 2004;  10 6179-6188
    CrossrefPubMedGoogle Scholar
  • 193 Hosaka Y, Higuchi T, Tsamagari M, Ischi H. Inhibition of invasion and experimental metastasis of murine melanoma cells by human soluble thrombomodulin.  Cancer Lett. 2000;  161 231-240
    CrossrefPubMedGoogle Scholar
  • 194 Hopewell J W, Calvo W, Jaenke R, Reinhold H S, Robbins M E, Whitehouse E M. Microvasculature and radiation damage.  Recent Results Cancer Res. 1993;  130 1-16
    PubMedGoogle Scholar
  • 195 Lyubimova N, Hopewell J W. Experimental evidence to support the hypothesis that damage to vascular endothelium plays the primary role in the development of late radiation - induced CNS injury.  Br J Radiol. 2004;  77 488-492
    PubMedGoogle Scholar
  • 196 Wang J, Zheng H, Ou X, Fink L M, Hauer-Jensen M. Deficiency of microvascular thrombomodulin and up-regulation of protease-activated receptor-1 in irradiaed rat intestine.  Am J Pathol. 2002;  160 2063-2072
    PubMedGoogle Scholar
  • 197 Wang J, Boerma M, Fu Q, Hauer-Jensen M. Significance of endothelial dysfunction in the pathogenesis of early and delayed radiation enteropathy.  World J Gastroenterol. 2007;  13 3047-3055
    PubMedGoogle Scholar
  • 198 Phillips D J, Greengard J S, Fernandez J A et al.. Protein S an antithrombotic factor, is synthesized and released by neural tumor cells.  J Neurochem. 1993;  61 344-347
    CrossrefPubMedGoogle Scholar
  • 199 Wimmel A, Rohner I, Ramaswamy A et al.. Synthesis and secrection of the anticoagulant protein S and coexpression of the Tyro3 receptor in human lung carcinoma cells.  Cancer. 1999;  86 43-49
    CrossrefPubMedGoogle Scholar
  • 200 Anderson H A, Maylock C A, Williams J A, Paweletz C P, Shu H, Shacter E. Serum-derived protein S binds to phosphatidilserine and stimulates the phagocytosis of apoptotic cells.  Nat Immunol. 2003;  4 87-91
    CrossrefPubMedGoogle Scholar
  • 201 Rezaie A R, Cooper S T, Church F C, Esmon C T. Protein C inhibitor is a potent inhibitor of thrombin-thrombomodulin complex.  J Biol Chem. 1995;  270 25336-25339
    CrossrefPubMedGoogle Scholar
  • 202 Rezende S M, Simmonds R E, Lane D A. Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex.  Blood. 2004;  103 1192-1201
    PubMedGoogle Scholar
  • 203 Heiring C, Dahlback B, Muller Y A. Ligand recognition and homophilic interactions in Tyro3: structural insights into the Axl/Tyro3 receptor tyrosine kinase family.  J Biol Chem. 2004;  279 6952-6958
    PubMedGoogle Scholar
  • 204 Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro3 family.  Science. 2001;  293 306-311
    CrossrefPubMedGoogle Scholar
  • 205 Tollefsen D M. Heparin cofactor II modulates the response to vascular injury.  Arterioscler Thromb Vasc Biol. 2007;  27 454-460
    CrossrefPubMedGoogle Scholar
  • 206 Tollefsen D M. Heparin cofactor II deficiency.  Arch Pathol Lab Med. 2002;  126 1394-1400
    PubMedGoogle Scholar
  • 207 Kario K, Matsuo T, Kodama K, Katayama S, Kobayashi H. Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with promyelocytic leukemia.  Thromb Res. 1992;  66 435-444
    CrossrefPubMedGoogle Scholar
  • 208 Foekens J A, Peters H A, Look M P et al.. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.  Cancer Res. 2000;  60 635-643
    PubMedGoogle Scholar
  • 209 Okusa Y, Ichikura T, Mochzuki H. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma.  Cancer. 1999;  85 1033-1038
    CrossrefPubMedGoogle Scholar
  • 210 Harvey S R, Sait S NJ, Xu I, Bailey J L, Penetrante R M, Marcus G. Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization.  Am J Pathol. 1999;  155 1115-1120
    PubMedGoogle Scholar
  • 211 Oka T, Ishida T, Nishino T, Sugimachi K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma.  Cancer Res. 1991;  51 3522-3525
    PubMedGoogle Scholar
  • 212 Evans C P, Elfman F, Parangi S, Conn M, Cuhna G, Shuman M A. Inhibition of protease cancer neovascularization and growth by urokinase-plasminogen activator receptor blockage.  Cancer Res. 1997;  57 3594-3599
    PubMedGoogle Scholar
  • 213 Kuhn W, Schmalfeld B, Reuning U et al.. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FOGO IIIc.  Br J Cancer. 1999;  79 1746-1751
    CrossrefPubMedGoogle Scholar
  • 214 de Witte J H, Sweep C G, Klijn J G et al.. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer.  Br J Cancer. 1999;  80 286-294
    CrossrefPubMedGoogle Scholar
  • 215 Franks A J, Elis E. Immunohistochemical localization of tissue plasminogen activator in human brain tumors.  Br J Cancer. 1989;  59 463-466
    PubMedGoogle Scholar
  • 216 Bajou K, Noel A, Gerard R D et al.. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularisation.  Nat Med. 1998;  4 923-927
    CrossrefPubMedGoogle Scholar
  • 217 Carmeliet P, Moons L, Dewerchin M et al.. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and plasminogen system.  Ann N Y Acad Sci. 1997;  811 191-206
    PubMedGoogle Scholar
  • 218 Heymans S, Luttun A, Nuyens D et al.. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.  Nat Med. 1999;  5 1135-1142
    CrossrefPubMedGoogle Scholar
  • 219 Manders P, Tjan-Heijnen V C, Span P N et al.. Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer.  Cancer Res. 2004;  64 659-664
    CrossrefPubMedGoogle Scholar
  • 220 Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S. Plasminogen activator system in human breast cancer.  Int J Cancer. 1992;  50 345-348
    PubMedGoogle Scholar
  • 221 Sakakibara T, Hibi K, Koike M et al.. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer.  Br J Cancer. 2005;  93 799-803
    CrossrefPubMedGoogle Scholar
  • 222 Sakakibara T, Hibi K, Koike M et al.. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer.  Cancer Sci. 2006;  97 395-399
    CrossrefPubMedGoogle Scholar
  • 223 Sakakibara T, Hibi K, Kodera Y, Ito K, Akiyama S, Nakao A. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of esophageal squamous cell carcinoma.  Clin Cancer Res. 2004;  10 1375-1378
    CrossrefPubMedGoogle Scholar
  • 224 Nagayama M, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.  Cancer. 1994;  73 1398-1405
    PubMedGoogle Scholar
  • 225 Hanekom G S, Stubbings H M, Kidson S H. The active fraction of plasmatic plasminogen activator inhibitor type 1 as a possible indicator of increased risk for metastatic melanoma.  Cancer Detect Prev. 2002;  26 50-59
    CrossrefPubMedGoogle Scholar
  • 226 Whitley B R, Palmieri D, Twerdi C D, Church F C. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.  Exp Cell Res. 2004;  296 151-162
    CrossrefPubMedGoogle Scholar
  • 227 Friedl P, Bröcker E B. The biology of cell locomotion within three-dimensional extracellular matrix.  Cell Mol Life Sci. 2000;  57 41-64
    CrossrefPubMedGoogle Scholar
  • 228 Estreicher A, Muhlhauser J, Carpentier J L, Orci L, Vassalli J D. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.  J Cell Biol. 1990;  111 783-792
    CrossrefPubMedGoogle Scholar
  • 229 Nykjaer A, Conese M, Christensen E I et al.. Recycling of the urokinase receptor upon internalization of the u-PA: serpin complexes.  EMBO J. 1997;  16 2610-2620
    CrossrefPubMedGoogle Scholar
  • 230 Wei Y, Waltz D A, Rao N et al.. Identification of the urokinase receptor as an adhesion receptor for vitronectin.  J Biol Chem. 1994;  269 32380-32388
    PubMedGoogle Scholar
  • 231 Deng G, Curriden S A, Hu G, Czekay R P, Loskutoff D J. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronect.  J Cell Physiol. 2001;  189 23-33
    CrossrefPubMedGoogle Scholar
  • 232 Takahashi T, Suzuki K, Ihara H, Mogami H, Kazui T, Urano T. Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v)beta(5) integrin.  Semin Thromb Hemost. 2005;  31 356-363
    Article in Thieme ConnectPubMedGoogle Scholar
  • 233 Scherrer A, Kruithof E K, Grob J P. Plasminogen activator inhibitor-2 in patients with monocytic leukemia.  Leukemia. 1991;  5 479-486
    PubMedGoogle Scholar
  • 234 Borgfeldt C, Bendahl P O, Gustavsson B et al.. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.  Int J Cancer. 2003;  107 658-665
    CrossrefPubMedGoogle Scholar
  • 235 Yoshino H, Endo Y, Watanabe Y, Sasaki T. Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis.  Br J Cancer. 1998;  78 833-839
    PubMedGoogle Scholar
  • 236 Zhao E, Han D, Yu Z, Fan E, Li Y, Zhou Z. Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx.  Lin Chuang Er Bi Yan Hou Ke Za Zhi.. 2002;  16 599-602
    PubMedGoogle Scholar
  • 237 Nordengren J, Fredstorp Lidebring M, Bendahl P O et al.. High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer.  Int J Cancer. 2002;  97 379-385
    CrossrefPubMedGoogle Scholar
  • 238 Foca C, Moses E K, Quinn M A, Rice G E. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.  Gynecol Oncol. 2000;  79 244-250
    CrossrefPubMedGoogle Scholar
  • 239 Osmak M, Babic D, Abramic M, Milicic D, Vrhovec I, Skrk J. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.  Neoplasma. 2001;  48 462-467
    PubMedGoogle Scholar
  • 240 Wojtukiewicz M Z, Sierko E, Zacharski L R, Rozanska-Kudelska M, Zimnoch L, Kisiel W. Occurence of components of fibrinolytic pathways in situ in laryngeal cancer.  Semin Thromb Hemost. 2003;  29 317-320
    Article in Thieme ConnectPubMedGoogle Scholar
  • 241 Mueller B M, Yu Y B, Laug W E. Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid / scid mice.  Proc Natl Acad Sci USA. 1995;  92 205-209
    CrossrefPubMedGoogle Scholar
  • 242 Laug W E, Cao X R, Yu Y B, Shimada H, Kruithof E K. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2.  Cancer Res. 1993;  53 6051-6057
    PubMedGoogle Scholar
  • 243 Yu H, Maurer F, Medcalf R L. Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation.  Blood. 2002;  99 2810-2818
    CrossrefPubMedGoogle Scholar
  • 244 Genton C, Kruithof E K, Schleuning W D. Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells.  J Cell Biol. 1987;  104 705-712
    CrossrefPubMedGoogle Scholar
  • 245 Medcalf R L, Kruithof E K, Schleuning W D. Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor / cachectin-responsive genes.  J Exp Med. 1988;  168 751-759
    CrossrefPubMedGoogle Scholar
  • 246 Darnell G A, Antalis T M, Johnstone R W et al.. Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif.  Mol Cell Biol. 2003;  23 6520-6532
    CrossrefPubMedGoogle Scholar
  • 247 Dickinson J L, Bates E J, Ferrante A, Antalis T M. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function.  J Biol Chem. 1995;  270 27894-27904
    CrossrefPubMedGoogle Scholar
  • 248 Dickinson J L, Norris B J, Jensen P H, Antalis T M. The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF-alpha induced apoptosis.  Cell Death Differ. 1998;  5 163-171
    CrossrefPubMedGoogle Scholar
  • 249 Fish R J, Kruithof E K. Evidence for serpinB2-independent protection from TNF-alpha-induced apoptosis.  Exp Cell Res. 2006;  312 350-361
    PubMedGoogle Scholar
  • 250 Stief T W, Radtke K P, Heimburger N. Inhibition of urokinase by protein C-inhibitor (PCI). Evidence for identity of PCI and plasminogen activator inhibitor 3.  Biol Chem Hoppe Seyler. 1987;  368 1427-1433
    PubMedGoogle Scholar
  • 251 Crisp R J, Knauer M F, Knauer D J. Protease nexin 1 is a potent urinary plasminogen activator inhibitor in the presence of collagen type IV.  J Biol Chem. 2002;  277 47285-47291
    CrossrefPubMedGoogle Scholar
  • 252 Rossignol P, Ho-Tin-Noe B, Vranckx R et al.. Protease nexin-1 inhibits plasminogen activation-induced apoptosis of adherent cells.  J Biol Chem. 2004;  279 10346-10356
    CrossrefPubMedGoogle Scholar
  • 253 Buchholz M, Biebl A, Neesse A et al.. SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo.  Cancer Res. 2003;  63 4945-4951
    PubMedGoogle Scholar
  • 254 Ozyilkan O, Baltali E, Ozdemir O, Tekuzman G, Kirazli S, Firat D. Haemostatic changes; plasma levels of alpha2-antiplasmin-plasmin complex and thrombin-antithrombin III complex in female breast cancer.  Tumori. 1998;  84 364-367
    PubMedGoogle Scholar
  • 255 Taguchi O, Gabazza E C, Yoshida M, Yamakami T, Kobayashi H, Shima T. High plasma level of plasmin-alpha 2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer.  Clin Chim Acta. 1996;  244 69-81
    CrossrefPubMedGoogle Scholar
  • 256 Hayashido Y, Hamana T, Ishida Y, Shintani T, Koizumi K, Okamoto T. Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion.  Oncol Rep. 2007;  17 417-423
    PubMedGoogle Scholar
  • 257 Reijerkerk A, Voest E E, Gebbink M F. No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer.  Eur J Cancer. 2000;  36 1695-1705
    CrossrefPubMedGoogle Scholar
  • 258 Meijers J C, Oudijk E J, Mosnier L O et al.. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia.  Br J Haematol. 2000;  108 518-523
    CrossrefPubMedGoogle Scholar
  • 259 Hataji O, Taguchi O, Gabazza E C et al.. Increased circulating levels of thrombin -acivatable fibrinolysis inhibitor in lung cancer patients.  Am J Hematol. 2004;  76 214-219
    CrossrefPubMedGoogle Scholar
  • 260 Nakasaki T, Wada H, Shigemori C et al.. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer.  Am J Hematol. 2002;  69 247-254
    Google Scholar
  • 261 Seto S, Onodera H, Kaido T et al.. Tissue factor expression in human colorectal carcinoma.  Cancer. 2000;  88 295-301
    CrossrefPubMedGoogle Scholar
  • 262 Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, Suzuki H. Tissue factor expression and metastatic potential of colorectal cancer.  Thromb Haemost. 1998;  80 894-898
    PubMedGoogle Scholar
  • 263 Bromberg M E, Sundaram R, Homer R J, Garen A, Konigsberg W H. Role of tissue factor in metastasis: function of the cytoplasmic and extracellular domains of the molecule.  Thromb Haemost. 1999;  82 88-92
    PubMedGoogle Scholar
  • 264 Amirkhosravi A, Meyer T, Warnes G et al.. Pentoxyfilline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor.  Thromb Haemost. 1998;  80 598-602
    PubMedGoogle Scholar
  • 265 Fenton II J W, Shen G X, Minnear F L et al.. Statins induce hypothrombotic states?.  Clin Appl Thromb Hemost. 2000;  6 18-21
    PubMedGoogle Scholar
  • 266 Rak J, Mitsuhashi Y, Sheehan C et al.. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts.  Cancer Res. 2000;  60 490-498
    PubMedGoogle Scholar
  • 267 Viloria-Petit A, Crombet T, Jothy S et al.. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.  Cancer Res. 2001;  61 5090-5101
    PubMedGoogle Scholar
  • 268 Attoub S, Rivat C, Rodrigues S et al.. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.  Cancer Res. 2002;  62 4879-4883
    PubMedGoogle Scholar
  • 269 Fletcher L. Approval heralds new generation of kinase inhibitors?.  Nat Biotechnol. 2001;  19 599-600
    PubMedGoogle Scholar
  • 270 Russo P, Ottoboni C, Falugi C et al.. Cellular effects of a new farnesyltransferase inhibitor, RPR-115135, in a human isogenic colon cancer cell line model system HCT-116.  Ann N Y Acad Sci. 1999;  886 252-256
    CrossrefPubMedGoogle Scholar
  • 271 Cirillo P, Golino P, Ragni M et al.. Long-lasting antithrombotic effects of a single dose of human recombinant, active site-blocked factor VII: insights into possible mechanism(s) of action.  J Thromb Haemost. 2003;  1 992-998
    CrossrefPubMedGoogle Scholar
  • 272 Soderstrom T, Hedner U, Arnljots B. Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury.  J Vasc Surg. 2001;  33 1072-1079
    CrossrefPubMedGoogle Scholar
  • 273 Rossi C, Hess S, Eckl R W et al.. Effect of MCM09, an active site-directed inhibitor of factor Xa, on B16-BL6 melanoma lung colonies in mice.  J Thromb Haemost. 2006;  4 608-613
    CrossrefPubMedGoogle Scholar
  • 274 Tomaru T, Nakamura F, Miwa A Y et al.. Antithrombin and thrombolytic effect of a new antithrombin agent: angioscopic and angiographic comparison with heparin or batroxobin.  J Interv Cardiol. 1994;  7 409-419
    CrossrefPubMedGoogle Scholar
  • 275 Sakuragi T, Sakao Y, Furukawa K et al.. Successful management of acute pulmonary embolism after surgery for lung cancer.  Eur J Cardiothorac Surg. 2003;  24 580-587
    CrossrefPubMedGoogle Scholar
  • 276 Asanuma K, Wakabayashi H, Okuyama N et al.. Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis.  Oncology. 2004;  67 166-173
    CrossrefPubMedGoogle Scholar
  • 277 Tsopanoglou N E, Maragoudakis M E. On the mechanism of thrombin-induced angiogenesis.  J Biol Chem. 1999;  274 23969-23976
    CrossrefPubMedGoogle Scholar
  • 278 Tsopanoglou N E, Pipili-Synetos E, Maragoudakis M E. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation.  Am J Physiol. 1993;  264 1302-1307
    PubMedGoogle Scholar
  • 279 Hua Y, Keep R F, Schallert T, Hoff J T, Xi G. A thrombin inhibitor reduces brain edema, glima mass and neurological deficits in a rat glioma model.  Acta Neurochir Suppl. 2003;  86 503-506
    PubMedGoogle Scholar
  • 280 Hua Y, Tang L L, Keep R F et al.. Systemic use of argatroban reduces tumor mass, attenuates neurological deficits and prolongs survival time in rat gliomas models.  Acta Neurochir Suppl. 2005;  95 403-406
    PubMedGoogle Scholar
  • 281 Hua Y, Tang L L, Keep R F et al.. The role of thrombin in gliomas.  J Thromb Haemost. 2005;  3 1917-1923
    CrossrefPubMedGoogle Scholar
  • 282 Sarker K P, Biswas K K, Yamaji K et al.. Inhibition of thrombin-induced vascular endothelial growth factor production in human neuroblastoma (NB-1) cells by argatroban.  Pathophysiol Haemost Thromb. 2005;  34 41-47
    CrossrefPubMedGoogle Scholar
  • 283 Gasic G J, Gasic T B, Steward C C. Antimetastatic effects associated with platelet reduction.  Proc Natl Acad Sci USA. 1968;  61 46-52
    PubMedGoogle Scholar
  • 284 Chiang H S, Swaim M W, Huang T F. The Arg-Gly-Asp-containing peptide, rhodostomin, inhibits in vitro cell adhesion to extracellular matrices and platelet aggregation caused by saos-2 human osteosarcoma cells.  Br J Cancer. 1995;  71 265-270
    PubMedGoogle Scholar
  • 285 Chiang H S, Swaim M W, Huang T F. Characterization of platelet aggregation induced by human breast carcinoma and its inhibition by snake venom peptides, trigramin and rhodostomin.  Breast Cancer Res Treat. 1995;  33 225-235
    CrossrefPubMedGoogle Scholar
  • 286 Sheu J R, Lin C H, Pung H C, Teng C M, Huang T F. Triflavin, an Arg-Gly-Asp-containing peptide, inhibits tumor cell-induced platelet aggregation.  Jpn J Cancer Res. 1993;  84 1062-1071
    PubMedGoogle Scholar
  • 287 Borsig L, Wong R, Feramisco J et al.. Heparin and cancer revised: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis.  Proc Natl Acad Sci USA. 2001;  98 3352-3357
    CrossrefPubMedGoogle Scholar
  • 288 Bernard G R, Margolis B D, Shanies H M et al.. Extended Evaluation of Recombinant Human Activated Protein C United States Investigators. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in sepsis.  Chest. 2004;  125 2206-2216
    CrossrefPubMedGoogle Scholar
  • 289 Shi X, Gangedharan B, Brass L F, Ruf W, Mueller B M. Protease-activated receptors (PAR-1 and PAR-2) contribute to tumor cell motility and metastasis.  Mol Cancer Res. 2004;  2 395-402
    PubMedGoogle Scholar
  • 290 Zania P, Kritikou S, Flordellis C S, Maragoudakis M E, Tsopanoglou N E. Blockage of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis.  J Pharmacol Exp Ther. 2006;  318 246-254
    CrossrefPubMedGoogle Scholar
  • 291 Domiano B P, Derian C K, Maryanoff B E, Zhang H C, Gordon P A. RWJ-58259: a selective antagonists of protease activated receptor-1.  Cardiovasc Drug Rev. 2003;  21 313-326
    PubMedGoogle Scholar
  • 292 Engelberg H. Action of heparin that may effect the malignant process.  Cancer. 1999;  85 257-272
    CrossrefPubMedGoogle Scholar
  • 293 Hull R D, Raskob G E, Pineo G F et al.. Subcutaneous low-molecular-weight-heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.  N Engl J Med. 1992;  326 975-982
    CrossrefPubMedGoogle Scholar
  • 294 Prandoni P, Lensing A WA, Büller H R et al.. Comparison of subcutaneous low-molecular-weight-heparin with intravenous standard heparin in proximal deep-vein thrombosis.  Lancet. 1992;  339 441-445
    CrossrefPubMedGoogle Scholar
  • 295 Hirsh J, Siragusa S, Cosmi B, Ginsber J S. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism.  Thromb Haemost. 1995;  74 360-363
    PubMedGoogle Scholar
  • 296 Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg J S. Low-molecular-weight-heparin and unfractionated heparin in the treatment of patients with acute venous thromboembolism.  Am J Med. 1996;  100 269-277
    CrossrefPubMedGoogle Scholar
  • 297 Klerk C P, Smorenburg S M, Otten H M et al.. The effect of low molecular weight heparin on survival in patients with advanced malignancy.  J Clin Oncol. 2005;  23 2130-2135
    CrossrefPubMedGoogle Scholar
  • 298 Altinbas M, Coskun H S, Er O et al.. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer.  J Thromb Haemost. 2004;  2 1266-1271
    CrossrefPubMedGoogle Scholar
  • 299 Lee A Y, Rickles F R, Julian J A et al.. Randomized comparison of low molecular weight heparin coumarin derivates on the survival of patients with cancer and venous thromboembolism.  J Clin Oncol. 2005;  23 2123-2129
    Google Scholar
  • 300 Vignoli A, Marchetti M, Balducci D, Barbui T, Falanga A. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties.  Haematologica. 2006;  91 207-214
    PubMedGoogle Scholar
  • 301 Mousa S A, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inibitor.  Thromb Haemost. 2004;  92 627-633
    Google Scholar
  • 302 Niers T M, Klerk C P, DiNisio M et al.. Mechanisms of heparin induced anti-cancer activity in experimental cancer models.  Crit Rev Oncol Hematol. 2007;  61 195-207
    PubMedGoogle Scholar
  • 303 Parish C R, Freeman C, Brown K J et al.. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.  Cancer Res. 1999;  59 3433-3441
    PubMedGoogle Scholar
  • 304 Colin S, Jeanny J C, Mascarelli F et al.. In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogeneous basic fibroblast growth factor.  Mol Pharmacol. 1999;  55 74-82
    PubMedGoogle Scholar
  • 305 Schlessinger J, Lax I, Lemmon M. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors?.  Cell. 1995;  83 357-360
    CrossrefPubMedGoogle Scholar
  • 306 Soker S, Goldstaub D, Svahn C M, Vlodavsky I, Levi B Z, Neufeld G. Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors.  Biochem Biophys Res Commun. 1994;  203 1339-1347
    CrossrefPubMedGoogle Scholar
  • 307 Norrby K, Østergaard P. A 5.0-kD heparin fraction systemically suppresses VEGF165-mediated angiogenesis.  Int J Microcirc Clin Exp. 1997;  17 314-321
    PubMedGoogle Scholar
  • 308 Norrby K, Østergaard P. Basic fibroblast growt factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-wieght than high-molecular-weight heparin.  Int J Microcirc Clin Exp. 1996;  16 8-15
    PubMedGoogle Scholar
  • 309 Balzarotti M, Fontana F, Marras C et al.. In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas.  Oncol Res. 2006;  16 245-250
    PubMedGoogle Scholar
  • 310 Chopra H, Timar J, Rong X et al.. Is there a role for the tumor cell integrin αIIbß3 in tumor-cell induced platelet aggregation.  Clin Exp Metastasis. 1992;  10 125-137
    CrossrefPubMedGoogle Scholar
  • 311 Coller B S. Anti-GpIIb/IIIa drugs: current strategies and future directions.  Thromb Haemost. 2001;  86 427-443
    PubMedGoogle Scholar
  • 312 Nierodzik M L, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo.  Thromb Haemost. 1995;  74 282-290
    PubMedGoogle Scholar
  • 313 Trikha M, Zhou Z, Timar J et al.. Multiple roles for platelet GPIIb/IIa and platelet alpha v beta 3 integrins in tumor growth, angiogenesis, and metastasis.  Cancer Res. 2002;  62 2824-2833
    PubMedGoogle Scholar
  • 314 Amirkhosravi A, Mousa S A, Amaya M et al.. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb-IIIa antagonist XV454.  Thromb Haemost. 2003;  90 549-554
    PubMedGoogle Scholar
  • 315 Sheu J R, Lin C H, Chung Jl, Teng C M, Huang T F. Triflavin, an Arg-Gly-Asp containing snake venom peptide, inhibits aggregation of human platelets induced by human hepatoma cell line.  Thromb Res. 1992;  66 679-691
    CrossrefPubMedGoogle Scholar
  • 316 Chiang H S, Swaim M W, Huang T F. Characterization of platelet aggregation induced by human colon adenocarcinoma cells and its inhibition by snake venom peptides, trigramin and rhodostomin.  Br J Haematol. 1994;  87 325-331
    PubMedGoogle Scholar
  • 317 Chiang H S, Swaim M W, Huang T F. The Arg-Gly-Asp-containing peptide, rhodostomin, inhibits in vitro cell adhesion to extracellular matrices and platelet aggregation caused by saos-2 human osteosarcoma cells.  Br J Cancer. 1995;  71 265-270
    PubMedGoogle Scholar
  • 318 Chiang H S, Swaim M W, Huang T F. Characterization of platelet aggregation induced by human breast carcinoma and its inhibition by snake venom peptides, trigramin and rhodostomin.  Breast Cancer Res Treat. 1995;  33 225-235
    CrossrefPubMedGoogle Scholar
  • 319 Lever R, Page C P. Novel drug development opportunities for heparin.  Nat Rev Drug Discov. 2002;  1 140-148
    CrossrefPubMedGoogle Scholar
  • 320 da Silva M S, Horton J A, Wijelath J M et al.. Heparin modulates integrin-mediated cellular adhesion: specificity of interaction with alpha and beta integrin subunits.  Cell Adhes Commun. 2003;  10 59-67
    PubMedGoogle Scholar
  • 321 Ludwig R J, Beohme B, Podda M et al.. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis.  Cancer Res. 2004;  64 2743-2750
    CrossrefPubMedGoogle Scholar
  • 322 Wang J, Zheng H, Ou X et al.. Hirudin ameliorates intestinal radiation toxicity in the rat: support for thrombin inhibition as strategy to minimize side-effects after radiation therapy and as countermeasure against radiation exposure.  J Thromb Haemost. 2004;  2 2027-2035
    CrossrefPubMedGoogle Scholar
  • 323 Glantz M J, Burger P C, Friedman A H, Radtke R A, Massey E W, Schold Jr S C. Treatment of radiation-induced nervous system injury with heparin and warfarin.  Neurology. 1994;  44 2020-2027
    CrossrefPubMedGoogle Scholar
  • 324 Wang J, Zheng H, Qiu X, Kulkarni A, Fink L M, Hauer-Jansen M. Modulation of the intestinal response to ionizing radiation by anticoagulant and non-anticoagulant heparins.  Thromb Haemost. 2005;  94 1054-1059
    PubMedGoogle Scholar
  • 325 Wang J, Albertson C M, Zheng H, Fink L M, Herbert J M, Hauer-Jensen M. Short-term inhibition of ADP-induced platelet aggregation by clopidogrel ameliorates radiation-induced toxicity in rat small intestine.  Thromb Haemost. 2002;  87 122-128
    PubMedGoogle Scholar
  • 326 Akyurek S, Atahan L, Cengiz M et al.. Effect of ticlopidine in the prevention of radiation enteropathy.  Br J Radiol. 2006;  79 409-414
    PubMedGoogle Scholar
  • 327 Mouthon M A, Gaugler M H, Vandamme M, Gourmelon P, Wagemaker G, Van der Meeren A. Ticlopidine inhibits the prothrombotic effects of thrombopoietin and ameliorates survival after supralethal total body irradiation.  Thromb Haemost. 2002;  87 323-328
    PubMedGoogle Scholar

Dr. Marek Z Wojtukiewicz

Department of Oncology, Medical University

12 Ogrodowa St., 15-027 Bialystok, Poland

Email: m.wojtukiewicz@neostrada.pl

      >